Moxifloxacin penetration into human gastrointestinal tissues

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 5, 2004, Pages 875-877

  Wirtz, Martin ^a   Kleeff, Jörg ^a   Swoboda, Stefanie ^a   Halaceli, Irfan ^a   Geiss, Heiko K ^a   Hoppe Tichy, Torsten ^a   Büchler, Markus W ^a   Friess, Helmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bacterial infection; Methoxyquinolone; Tissue concentrations

Indexed keywords

ANTIINFECTIVE AGENT; LEVOFLOXACIN; METRONIDAZOLE; MEZLOCILLIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CLINICAL ARTICLE; COLON MUCOSA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL SURGERY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; NAUSEA; PREOPERATIVE PERIOD; SMALL INTESTINE MUCOSA; STOMACH MUCOSA;

ADULT; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; COLON; DIGESTIVE SYSTEM; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINE, SMALL; MALE; MIDDLE AGED; QUINOLINES; SPECTROMETRY, FLUORESCENCE; STOMACH;

EID: 2442669075     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh173     Document Type: Article

References (9)

1. Edlund, C., Beyer, G., Hiemer-Bau, M. et al. (2000). Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scandinavian Journal of Infectious Diseases 32, 81-5.
2. Blondeau, J. M. (1999). A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'. Journal of Antimicrobial Chemotherapy 43, Suppl. B, 1-11.
3. Stass, H. & Dalhoff, A. (1997). Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. Journal of Chromatography B, Biomedical Sciences and Applications 702, 163-74.
4. Bottcher, S., von Baum, H., Hoppe-Tichy, T. et al. (2001). An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum. Journal of Pharmaceutical and Biomedical Analysis 25, 197-203.
5. Eichler, H. G. & Muller, M. (1998). Drug distribution. The forgotten relative in clinical pharmacokinetics. Clinical Pharmacokinetics; 34, 95-9.
6. Aldridge, K. E. & Ashcraft, D. S. (1997). Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrobial Agents and Chemotherapy 41, 709-11.
7. Stass, H. & Kubitza, D. (1999). Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. Journal of Antimicrobial Chemotherapy 43, Suppl. B, 83-90.
8. Sanchez, J. E., Saenz, N. G., Rincon, M. R. et al. (2000). Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. Journal of Antimicrobial Chemotherapy 46, 283-5.
9. Di Caro, S., Ojetti, V., Zocco, M. A. et al. (2002). Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics 16, 527-32.